Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
Status:
Completed
Trial end date:
2020-10-26
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate safety and tolerability as defined by the
frequency of the adverse events (AEs) of flu-like symptoms (FLS) [chills, pyrexia, myalgia,
and asthenia], injection site reactions (ISRs), and injection site reaction pain (ISR-P),
over 24 weeks of treatment (the active comparator period) with PLEGRIDY 125 microgram (μg)
subcutaneous (SC) every 2 weeks versus current SC IFN-β therapy in participants with
Relapsing Remitting Multiple Sclerosis (RRMS).